Achieve Life Sciences Inc
$ 4.88
7.25%
03 Dec - close price
- Market Cap 259,782,000 USD
- Current Price $ 4.88
- High / Low $ 4.92 / 4.45
- Stock P/E N/A
- Book Value 0.64
- EPS -1.35
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.65 %
- ROE -1.61 %
- 52 Week High 5.78
- 52 Week Low 1.84
About
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company based in Vancouver, focused on developing innovative solutions to combat smoking and nicotine addiction. Its lead product, cytisinicline, has demonstrated efficacy in promoting smoking cessation, supported by robust clinical trial data. By addressing the urgent public health challenge of tobacco dependence, Achieve aims to significantly improve patient outcomes while reducing the adverse effects of tobacco use. With a commitment to advancing its therapeutic programs, Achieve Life Sciences is strategically positioned to make a lasting impact on addiction treatment both in the United States and globally.
Analyst Target Price
$15.89
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-26 | 2024-11-07 | 2024-08-13 | 2024-05-09 | 2024-03-13 | 2023-11-09 | 2023-08-14 | 2023-05-09 | 2023-03-16 |
| Reported EPS | -0.28 | -0.37 | -0.37 | -0.36 | -0.36 | -0.25 | -0.26 | -0.26 | -0.34 | -0.43 | -0.5 | -0.83 |
| Estimated EPS | -0.244 | -0.37 | -0.3657 | -0.36 | -0.26 | -0.23 | -0.24 | -0.31 | -0.38 | -0.42 | -0.69 | -0.83 |
| Surprise | -0.036 | 0 | -0.0043 | 0 | -0.1 | -0.02 | -0.02 | 0.05 | 0.04 | -0.01 | 0.19 | 0 |
| Surprise Percentage | -14.7541% | 0% | -1.1758% | 0% | -38.4615% | -8.6957% | -8.3333% | 16.129% | 10.5263% | -2.381% | 27.5362% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ACHV
2025-10-18 00:08:03
This article reports that the FDA has granted a priority review voucher for cytisinicline, a potential vaping cessation aid. However, the full content of the article is unavailable due to an application error on the website.
2025-10-17 22:28:57
This article reports on an application error encountered when trying to load content from ng.investing.com. It indicates a client-side exception preventing the display of the intended news about the FDA granting a priority voucher for cytisinicline as a vaping cessation aid. The actual content of the news story is not available due to this error.
2025-10-17 16:15:39
The article reports an application error encountered while loading the Investing.com South Africa website. It mentions that Premium AI-picked stock strategies are available for South African stocks and 15 additional markets, suggesting that the primary content was likely about the FDA granting a priority voucher for cytisinicline. The full article content is not displayed due to the error.
2025-10-17 14:32:12
Achieve Life Sciences' stock rose significantly after receiving a Priority Voucher from the FDA for its e-cigarette dependence treatment, cytisinicline. This voucher expedites the review process for the drug, which has shown clinical efficacy in trials. The company's New Drug Application for cytisinicline for smoking cessation has already been accepted by the FDA.
2025-10-17 13:26:42
This article indicates that Achieve Life Sciences' stock soared after the company received an FDA priority voucher. However, the full content of the article is unavailable due to an application error.
2025-10-17 13:10:49
This article indicates an application error on Investing.com prevented the display of the full news content regarding Achieve Life Sciences. The original headline suggests that Achieve Life Sciences stock soared due to receiving an FDA priority review voucher. However, the actual content of the article is unavailable.
